2017 Regular Session
|At the request of:|
|Chief Sponsors:||Representative Williamson, Buehler, Greenlick, Hernandez, Kennemer, Malstrom, Meek, Senator Steiner Hayward|
|Regular Sponsors:||Representative Alonso Leon, Bynum, Fahey, Keny-Guyer, McKeown, Sollman, Senator Monnes Anderson|
|Bill Title:||Relating to drugs; and prescribing an effective date.|
|Catchline/Summary:||Removes special training requirement from statutes governing prescribing, dispensing and distributing naloxone.
Specifies that reimbursing cost of medication prescribed for purpose of treating opioid or opiate withdrawal does not require prior authorization during first 30 days of treatment. Specifies that individual may not be denied entry into specialty court in this state solely for reason that individual is taking, or intends to take, medication prescribed by licensed health care practitioner for treatment of drug abuse or dependency. Requires Oregon Health Authority to publish and report information related to opioids and opiates. Requires pharmacy to report deidentified information to prescription monitoring program upon dispensing prescribed naloxone. Requires pharmacy to report certain other identifying information to prescription monitoring program upon dispensing prescribed controlled substance classified in schedules II through IV. Requires information to be disclosed from prescription monitoring program to medical director or pharmacy director. Requires information to be disclosed from prescription monitoring program for certain other purposes. Requires licensing information of licensees who are authorized to prescribe or dispense controlled substances to be provided to authority for purpose of qualifying licensees to report information to, or receive information from, prescription monitoring program. Specifies that authority may require person requesting deidentified information from prescription monitoring program to enter into data use agreement with authority. Requires authority, not less than once per year, to develop, through use of prescription monitoring information, criteria by which practitioner may be required to receive education or training on prescribing of opioids or opiates. Creates Prescription Monitoring Program Prescribing Practices Review Subcommittee for purposes of advising authority on development of criteria, reviewing practitioner's history to determine whether practitioner meets criteria and directing authority to provide educational material to practitioner who meets criteria. Provides that authority may enter into agreements governing sharing and use of information reported to prescription monitoring program with regulatory authorities of other states that administer prescription monitoring programs. Provides that prescription monitoring program provisions become operative January 1, 2018. Takes effect on 91st day following adjournment sine die.
|Chapter Number:||Chapter 683|
|Fiscal Impact:||Fiscal Impact Issued|
|Revenue Impact:||No Revenue Impact|
|Measure Analysis:||Staff Measure Summary / Impact Statements|
|Current Location:||Chapter Number Assigned|